A mid-stage trial of BPL‑003 nasal spray shows promising results for treatment-resistant depression, igniting biotech ...

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

None have been approved by the Food and Drug Administration so far, though in 2019, Johnson & Johnson received FDA permission ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...